On June 2, 2026, Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. Wilson Sonsini Goodrich & Rosati advised BVF Partners on IP matters related to the transaction.

The proceeds from the Series B financing will support the late-stage development of NES/T Gel, an investigational hormonal, reversible male contraceptive with first-in-class potential. 

The Wilson Sonsini team that advised BVP Partners on IP matters included Michael Hostetler, Victoria Cheng, Jane Yang, and Carey Cling.

For more information, please see Contraline’s news release.